Refill Gaps and Adherence Coordination in Peptide Therapy: What Clinics Can Measure

Question: For a peptide clinic, which adherence and refill problems can be handled by administrative coordination, and what should be measured so the clinic can see the problem without crossing into clinical advice?

Type: Sourced desk research.

Method

This review reads official public-health, program, and drug resources to establish the general framework for medication continuity and patient communication, and it reads the privacy rule that governs outreach. The evidence base is:

• The Centers for Disease Control and Prevention, which publishes public-health guidance and data on chronic disease and medication use.
• The Substance Abuse and Mental Health Services Administration, which publishes behavioral-health resources that bear on continuity of care.
• The official Medicare resource, which describes coverage and beneficiary-facing processes.
• The CMS administrative simplification materials, which describe standard health care transactions including eligibility and claims.
• 45 CFR 164.502, which governs uses and disclosures of protected health information.
• The FDA drug resources, used to confirm the regulated product context.

The method is qualitative. I distinguish the administrative coordination task (find the gap, classify the likely cause, route it, and document the contact) from the clinical task (decide whether a therapy should continue or change). Statements drawn from the sources are labeled source facts; process recommendations are labeled interpretation. This is a synthesis, and it deliberately does not provide medical advice, dosing guidance, or treatment recommendations.

What the sources say

Continuity of care is a recognized public-health concern. The CDC publishes guidance and data on chronic and preventive care, including the importance of continuity and follow-up. (Source fact.) The operational implication for a clinic is that follow-up is a process worth designing, not an occasional courtesy. (Interpretation.)

Behavioral and social factors affect continuity. SAMHSA publishes resources addressing behavioral-health and social factors that influence whether people remain engaged with care. (Source fact.) A refill gap can therefore reflect a barrier that is not clinical at all. (Interpretation.)

Beneficiary-facing processes exist and can be tracked. The official Medicare resource describes coverage and processes available to beneficiaries, including how to ask questions about coverage and appeals. (Source fact.) When a patient disengages because of a coverage question, the clinic's coordination work runs in parallel with a process the patient can also pursue. (Interpretation.)

Standard transactions support eligibility checks. The CMS administrative simplification materials describe standard health care transactions, including the eligibility and claims transactions that most practices use. (Source facts.) Eligibility checking is a concrete, permitted administrative step that can explain some gaps before they are labeled as non-adherence. (Interpretation.)

Patient communication is protected health information. 45 CFR 164.502 limits the use and disclosure of protected health information. (Source fact.) Outreach by phone, text, portal, or email must fit within the applicable permissions and safeguards, and remote coordination staff should be trained accordingly. (Interpretation.)

The product context is regulated. The FDA drug resources describe the oversight framework for drug products. (Source fact.) A peptide therapy sits inside that framework, and the clinic's administrative work should respect the boundary between coordination and clinical decision-making. (Interpretation.)

Continuity is described as a system property. Public-health resources frame continuity and engagement as outcomes influenced by access, communication, and support rather than by a single actor's decision. The CDC publishes chronic and preventive care guidance, and SAMHSA publishes behavioral-health resources addressing factors that affect engagement. (Source facts plus interpretation.) For a peptide clinic, that framing supports a clean division of labor: coordinate and document the non-clinical work, and route the clinical decisions to the people licensed to make them.

Findings

1. A refill gap is a signal with several possible causes. A missed refill can reflect a clinical review that has not happened, a coverage or cost barrier, a supply or fulfillment delay, a communication that did not reach the patient, or a decision to stop. Classifying the cause is the first coordination task. (Synthesis of the CDC, SAMHSA, and Medicare sources.)
2. The administrative task is to surface and route, not to decide. The coordination specialist can identify the gap, make the permitted contact, collect the non-clinical facts, and route the case. The clinical question goes to the clinician. This is the boundary that keeps a coordination role safe and useful. (Interpretation.)
3. Coverage questions are checkable. Because standard eligibility transactions exist, an eligibility check is a legitimate early step in triage. (Synthesis of the administrative simplification source.)
4. Outreach has privacy constraints. Because patient communication is protected health information, the channel, the recipient, and the content all need to fit within the rules. (Synthesis of 164.502.)
5. The measure should separate administrative and clinical time. The interval from gap detection to first successful contact is an administrative measure. The interval from clinical question to clinical decision is not. Mixing them hides where the delay is. (Interpretation.)
6. Privacy applies to every outreach channel. Because 45 CFR 164.502 governs uses and disclosures, both the channel and the content of a refill reminder matter. A reminder that reveals more than necessary to the wrong recipient is a privacy problem, not only a service failure, so coordination scripts and message templates should be reviewed for the minimum necessary content. (Synthesis of 164.502.)
7. A recurring cause is a process fix, not a patient problem. When the same cause appears repeatedly, the useful response is usually a change to instructions, reminder timing, or routing. Treating every gap as an individual patient failure hides the systemic pattern. (Interpretation.)

Operational implications

Translating the sources into coordination checkpoints for a peptide clinic, with qualified clinical and compliance advisors confirming the specifics:

• Define gap detection rules in workflow terms. For example, a missed expected refill date or an unanswered outreach after a defined interval. Keep the rule administrative and configurable.
• Use a small, documented cause taxonomy. Clinical review needed; coverage or cost; supply or fulfillment; contact failure; patient decision; unknown. Assign an owner to each.
• Route clinical questions to clinicians. Coordination staff should not advise on continuation, dosing, or alternatives.
• Check eligibility before concluding non-adherence. Use the standard eligibility process where applicable.
• Keep contact attempts documented and privacy-compliant. Record channel, date, outcome, and the next action, and follow the applicable privacy rules.
• Measure detection-to-contact time separately from clinical decision time. This is the clearest way to show whether the bottleneck is coordination or clinical capacity.
• Review the taxonomy quarterly. Recurring causes point to process fixes, such as clearer refill instructions or a better reminder cadence.

A proposed minimum measurement set, offered as a starting point rather than a standard: number of detected gaps per period; percentage of gaps classified by cause; median detection-to-first-contact time; percentage of gaps with a documented disposition; and percentage of outreach attempts that followed the privacy process.

Limitations

This review reads public-health and program resources and the privacy rule, not clinical trial evidence, payer policy, or clinical guidelines. It does not evaluate whether any therapy is appropriate, effective, or safe, and it provides no medical advice or dosing guidance. It does not address state privacy or consent rules, which can be stricter, or the specific communication rules of any software platform. The cause taxonomy and measures are proposals, not validated instruments, and they should be adapted to the clinic's clinical and operational reality. Statistical claims about adherence are deliberately not asserted here because they depend on the specific therapy, population, and study design. Readers should confirm clinical and compliance specifics with qualified professionals before relying on this synthesis.

Sources

• Centers for Disease Control and Prevention, public health guidance and data (checked September 18, 2026): https://www.cdc.gov/
• Substance Abuse and Mental Health Services Administration, behavioral health resources (checked September 18, 2026): https://www.samhsa.gov/
• Medicare.gov, official Medicare consumer resource (checked September 18, 2026): https://www.medicare.gov/
• Centers for Medicare & Medicaid Services, Administrative Simplification (checked September 18, 2026): https://www.cms.gov/medicare/regulations-guidance/administrative-simplification
• 45 CFR 164.502, Uses and disclosures of protected health information (checked September 18, 2026): https://www.ecfr.gov/current/title-45/section-164.502
• U.S. Food and Drug Administration, Drugs (context confirmation, checked September 18, 2026): https://www.fda.gov/drugs